John Smither Buys Shares in Genelux Corporation

On June 16, 2026, John Smither acquired 31,566 shares of Genelux Corporation, which trades on the NasdaqCM under the ticker GNLX. This transaction adds to his stake in the biotechnology company, known for developing oncolytic viral immunotherapies.

Insider Buying and Selling at Genelux Corporation

John Smither wasn't alone in showing interest in Genelux Corporation. On the same day, insiders like James Tyree, Mary Mirabelli, and John Thomas each bought 31,566 shares. Yong Yu, the Chief Scientific Officer, made a larger purchase of 119,318 shares. None of these transactions were part of a pre-planned trading arrangement.

Other Institutional Activity in Genelux Corporation

Several institutional investors have also adjusted their positions in Genelux. Vanguard Capital Management LLC made a substantial addition, now holding 1,695,480 shares worth approximately $4.1 million. Bleichroeder LP increased its holdings by 666,666 shares, now owning 1,380,666 shares valued at about $3.3 million. Geode Capital Management, LLC added 72,354 shares, bringing its total to 453,761 shares worth $1.1 million. Meanwhile, Bank of America Corp /DE/ reduced its stake by 12,156 shares, now holding 323,865 shares valued at $783,753.

Genelux Corporation Stock Up 11.5%

Genelux Corporation shares were trading at $2.96. The company has a market cap of approximately $133 million and a forward P/E ratio that isn't meaningful due to lack of profitability. The stock's 52-week range is between $2.29 and $8.54. Genelux has a 50-day moving average of $2.84 and a 200-day moving average of $3.73. The company's beta is 0.55, indicating lower volatility compared to the market.

Analysts Set New Price Targets

On March 20, 2026, Benchmark maintained its 'buy' rating with a price target of $20. Previously, HC Wainwright & Co. reiterated its 'buy' rating with a target of $30 on March 25, 2025. The consensus among analysts is a 'buy' rating, with an average target price of $17.5 based on six opinions.

About Genelux Corporation

Genelux Corporation, headquartered in Westlake Village, California, is a clinical-stage biopharmaceutical company. It focuses on developing oncolytic viral immunotherapies for aggressive solid tumors. Its main product, Olvi-Vec, is a modified vaccinia virus designed to treat ovarian cancer. The company also has a technology platform called CHOICE and a library of oncolytic VACV immunotherapeutic candidates. Genelux collaborates with Newsoara BioPharma for research and commercialization in China.

Bottom Line

John Smither's recent purchase of Genelux shares highlights ongoing insider interest in the company. Investors track such moves to gauge confidence in the firm's future. It's important to remember that these insider transactions are reported after they occur, providing a historical view rather than a current snapshot of holdings.